Evaluation of <sup>11</sup>C-Acetate and <sup>18</sup> F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma

Paul Territo, Mary Maluccio, Amanda A. Riley, Brian P. McCarthy, James Fletcher, Mark Tann, Romil Saxena, N. Skill

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to evaluate modalities of PET/CT in MDR2<sup>-/-</sup> mice in order to facilitate therapeutic translational studies from bench to bedside. Methods: <sup>18</sup>F-FDG and <sup>11</sup>C-acetate PET/CT was performed on 12 m MDR2<sup>-/-</sup> mice (n = 3/tracer) with HCC and 12 m MDR2<sup>-/+</sup> control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α (TNFα) were quantified in 3-12 m MDR2<sup>-/-</sup> (n = 10) mice using commercially available ELISA analysis. To translate results in mice to patients <sup>11</sup>C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following treatment and currently on the liver transplant wait list. Results: Hepatic<sup>18</sup>F-FDG metabolism was not significantly increased in MDR2<sup>-/-</sup> mice. In contrast, hepatic <sup>11</sup>C-acetate metabolism was significantly elevated in MDR2<sup>-/-</sup> mice when compared to MDR2<sup>-/+</sup> controls. Serum AFP and LPA levels increased in MDR2<sup>-/-</sup> mice contemporaneous with the emergence of HCC. This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false <sup>11</sup>C-acetate negative. Conclusions: Hepatic <sup>11</sup>C-acetate PET/CT tracks well with HCC in MDR2<sup>-/-</sup> mice and patients with underlying liver disease. Consequently <sup>11</sup>C-acetate PET/CT is well suited to study 1) HCC emergence/progression in patients and 2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.

Original languageEnglish
Article number15
JournalBMC Medical Imaging
Volume15
Issue number1
DOIs
StatePublished - May 16 2015

Fingerprint

MDR Genes
Hepatocellular Carcinoma
Multiple Drug Resistance
Liver
carbon-11 acetate
alpha-Fetoproteins
Tumor Necrosis Factor-alpha
Serum
Recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Evaluation of <sup>11</sup>C-Acetate and <sup>18</sup> F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. / Territo, Paul; Maluccio, Mary; Riley, Amanda A.; McCarthy, Brian P.; Fletcher, James; Tann, Mark; Saxena, Romil; Skill, N.

In: BMC Medical Imaging, Vol. 15, No. 1, 15, 16.05.2015.

Research output: Contribution to journalArticle

@article{39121060473b487689852223823c7556,
title = "Evaluation of 11C-Acetate and 18 F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma",
abstract = "Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to evaluate modalities of PET/CT in MDR2-/- mice in order to facilitate therapeutic translational studies from bench to bedside. Methods: 18F-FDG and 11C-acetate PET/CT was performed on 12 m MDR2-/- mice (n = 3/tracer) with HCC and 12 m MDR2-/+ control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α (TNFα) were quantified in 3-12 m MDR2-/- (n = 10) mice using commercially available ELISA analysis. To translate results in mice to patients 11C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following treatment and currently on the liver transplant wait list. Results: Hepatic18F-FDG metabolism was not significantly increased in MDR2-/- mice. In contrast, hepatic 11C-acetate metabolism was significantly elevated in MDR2-/- mice when compared to MDR2-/+ controls. Serum AFP and LPA levels increased in MDR2-/- mice contemporaneous with the emergence of HCC. This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative. Conclusions: Hepatic 11C-acetate PET/CT tracks well with HCC in MDR2-/- mice and patients with underlying liver disease. Consequently 11C-acetate PET/CT is well suited to study 1) HCC emergence/progression in patients and 2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.",
author = "Paul Territo and Mary Maluccio and Riley, {Amanda A.} and McCarthy, {Brian P.} and James Fletcher and Mark Tann and Romil Saxena and N. Skill",
year = "2015",
month = "5",
day = "16",
doi = "10.1186/s12880-015-0058-z",
language = "English",
volume = "15",
journal = "BMC Medical Imaging",
issn = "1471-2342",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Evaluation of 11C-Acetate and 18 F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma

AU - Territo, Paul

AU - Maluccio, Mary

AU - Riley, Amanda A.

AU - McCarthy, Brian P.

AU - Fletcher, James

AU - Tann, Mark

AU - Saxena, Romil

AU - Skill, N.

PY - 2015/5/16

Y1 - 2015/5/16

N2 - Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to evaluate modalities of PET/CT in MDR2-/- mice in order to facilitate therapeutic translational studies from bench to bedside. Methods: 18F-FDG and 11C-acetate PET/CT was performed on 12 m MDR2-/- mice (n = 3/tracer) with HCC and 12 m MDR2-/+ control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α (TNFα) were quantified in 3-12 m MDR2-/- (n = 10) mice using commercially available ELISA analysis. To translate results in mice to patients 11C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following treatment and currently on the liver transplant wait list. Results: Hepatic18F-FDG metabolism was not significantly increased in MDR2-/- mice. In contrast, hepatic 11C-acetate metabolism was significantly elevated in MDR2-/- mice when compared to MDR2-/+ controls. Serum AFP and LPA levels increased in MDR2-/- mice contemporaneous with the emergence of HCC. This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative. Conclusions: Hepatic 11C-acetate PET/CT tracks well with HCC in MDR2-/- mice and patients with underlying liver disease. Consequently 11C-acetate PET/CT is well suited to study 1) HCC emergence/progression in patients and 2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.

AB - Background: Hepatocellular carcinoma (HCC) remains a global health problem with unique diagnostic and therapeutic challenges, including difficulties in identifying the highest risk patients. Previous work from our lab has established the murine multidrug resistance-2 mouse (MDR2) model of HCC as a reasonable preclinical model that parallels the changes seen in human inflammatory associated HCC. The purpose of this study is to evaluate modalities of PET/CT in MDR2-/- mice in order to facilitate therapeutic translational studies from bench to bedside. Methods: 18F-FDG and 11C-acetate PET/CT was performed on 12 m MDR2-/- mice (n = 3/tracer) with HCC and 12 m MDR2-/+ control mice (n = 3/tracer) without HCC. To compare PET/CT to biological markers of HCC and cellular function, serum alpha-fetoprotein (AFP), lysophosphatidic acid (LPA), cAMP and hepatic tumor necrosis factor α (TNFα) were quantified in 3-12 m MDR2-/- (n = 10) mice using commercially available ELISA analysis. To translate results in mice to patients 11C-acetate PET/CT was also performed in 8 patents suspected of HCC recurrence following treatment and currently on the liver transplant wait list. Results: Hepatic18F-FDG metabolism was not significantly increased in MDR2-/- mice. In contrast, hepatic 11C-acetate metabolism was significantly elevated in MDR2-/- mice when compared to MDR2-/+ controls. Serum AFP and LPA levels increased in MDR2-/- mice contemporaneous with the emergence of HCC. This was accompanied by a significant decrease in serum cAMP levels and an increase in hepatic TNFα. In patients suspected of HCC recurrence there were 5 true positives, 2 true negatives and 1 suspected false 11C-acetate negative. Conclusions: Hepatic 11C-acetate PET/CT tracks well with HCC in MDR2-/- mice and patients with underlying liver disease. Consequently 11C-acetate PET/CT is well suited to study 1) HCC emergence/progression in patients and 2) reduce animal numbers required to study new chemotherapeutics in murine models of HCC.

UR - http://www.scopus.com/inward/record.url?scp=84929413849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929413849&partnerID=8YFLogxK

U2 - 10.1186/s12880-015-0058-z

DO - 10.1186/s12880-015-0058-z

M3 - Article

C2 - 25981587

AN - SCOPUS:84929428240

VL - 15

JO - BMC Medical Imaging

JF - BMC Medical Imaging

SN - 1471-2342

IS - 1

M1 - 15

ER -